Unfolding story of inclusion-body myositis and myopathies: Role of misfolded proteins, amyloid-β, cholesterol, and aging

Journal of Child Neurology

Volumn 18, Issue 3, 2003, Pages 185-190

  Askanas, Valerie ^a   Engel, W King ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CHOLESTEROL; PROTEIN PRECURSOR;

ALZHEIMER DISEASE; ARTICLE; BIOACCUMULATION; CELL AGING; CELL INCLUSION; CHOLESTEROL TRANSPORT; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISABILITY; DISEASE SEVERITY; GENETIC DISORDER; GENETIC TRANSCRIPTION; HUMAN; INCLUSION BODY MYOSITIS; LIPID METABOLISM; MEDICAL RESEARCH; MUSCLE CELL; MUSCLE DISEASE; MYOPATHY; OXIDATIVE STRESS; PATHOGENESIS; PATHOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING;

EID: 0038407678     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738030180030401     Document Type: Article

References (48)

1. Hilton-Jones D: Inflammatory muscle diseases. Curr Opin Neurol 2001;14:591-596.
2. Dalakas MC: The molecular and cellular pathology of inflammatory muscle diseases. Curr Opin Pharmacol 2001;1:300-306.
3. Mendell J: New insights, current concepts in the pathophysiology of inflammatory myopathies. Adv Immunotherapy 2001;8:12-16.
4. Engel WK, Askanas V: Treatment of inclusion-body myositis and hereditary inclusion-body myopathy with reference to pathogenic mechanism. Personal experiences, in Askanas V, Serratrice G, Engel WK (eds): Inclusion-Body Myositis and Myopathies. Cambridge, United Kingdom: Cambridge University Press, 1998, 351-382.
5. Askanas V, Engel WK: Inclusion-body myositis: Newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol 2001;60:1-14.
6. Jin LW, Hearn MG, Ogburn CE, et al: Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-s myopathy similar to human inclusion body myositis. Am J Pathol 1998;153:1679-1686.
7. Fukuchi K, Pham D, Hart M, et al: Amyloid-beta deposition in skeletal muscle of transgenic mice: Possible model of inclusion body myopathy. Am J Pathol 1998;153:1687-1693.
8. Sugarman MC, Yamasaki TR, Oddo S, et al: Inclusion body myositis-like phenotype induced by transgenic overexpression of βAPP in skeletal muscle. Proc Natl Acad Sci U S A 2002;99:8334-8339.
9. Gallardo E, Rojas-Garcia R, de Luna N, et al: Inflammation in dysferlin myopathy: Immunohistochemical characterization of 13 patients. Neurology 2001;57:2136-2138.
10. Di Blasi C, Mora M, Pareyson D, et al: Partial laminin α2 chain deficiency in a patient with myopathy resembling inclusion body myositis. Ann Neurol 2000;47:811-816.
11. Fitzsimmons RB: Facioscapulohumeral muscular dystrophy. Curr Opin Neurol 1999;12:501-511.
12. Askanas V, Engel WK: New advances in inclusion-body myositis. Curr Opin Rheumatol 1993;5:732-741.
13. Askanas V, Engel WK: Hereditary inclusion-body myopathies, in Rosenberg RN, Prusiner SB, DiMauro S, et al (eds): The Molecular and Genetic Basis of Neurologic and Psychiatric Disease, 3rd ed. Philadelphia: Butterworth-Heinemann, in press.
14. Yunis EJ, Samaha FJ: Inclusion body myositis. Lab Invest 1971;25:240-248.
15. Askanas V, Engel WK: Newest approaches to diagnosis and pathogenesis of sporadic inclusion-body myositis and hereditary inclusion-body myopathies, including molecular-pathologic similarities to Alzheimer disease, in Askanas V, Serratrice G, Engel WK (eds): Inclusion-Body Myositis and Myopathies. Cambridge, United Kingdom: Cambridge University Press, 1998, 3-78.
16. Askanas V, Engel WK: Late-juvenile sporadic inclusion body myositis: A newly recognized syndrome. Ann Neurol 2000;48:439-440.
17. Askanas V, Engel WK, Alvarez RB, et al: Inclusion body myositis, muscle blood vessel and cardiac amyloidosis, and transthyretin Vall22lle Allele. Ann Neurol 2000;47:544-549.
18. Eisenberg I, Avidan N, Potikha T, et al: The UDP-N-acetylglucosamine 2-epimerase/N acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet 2001;29:83-87.
19. Tomimitsu H, Ishikawa K, Shimizu J, et al: Distal myopathy with rimmed vacuoles: Novel mutations in the GNE gene. Neurology 2002;59(Suppl 3):451-454.
20. Arai A, Tanaka K, Ikeuchi T, et al: A novel mutation in the GNE gene and a linkage disequilibrium in Japanese pedigrees. Ann Neurol 2002;52:516-519.
21. Vasconcelos OM, Raghavan R, Granger R, et al: Detection of two mutant alleles in the UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene (GNE) in a cohort of patients with sporadic and hereditary inclusion body myopathies (IBM). Neurology 2002;58(Suppl 3):A390.
22. Stäschet, Hinderlich S, Weise C, et al: A bifunctional enzyme catalyzes the first two steps in N-acetylneuraminic acid biosynthesis of rat liver. J Biol Chem 1997;272:24319-24324.
23. Lucka L, Krause M, Danker K, et al: Primary structure and expression analysis of human UDP-N-acetyl-glucosamine-2-epimerase/N-acetylmannosamine kinase, the bifunctional enzyme in neuraminic acid biosynthesis. FEBS Lett 1999;454:341-344.
24. Keppler OT, Hinderlich S, Langner J, et al: UDP-GlcNAc 2-epimerase: A regulator of cell surface sialylation. Science 1999;284:1372-1376.
25. Askanas V, Engel WK, Alvarez RB: Enhanced detection of congored positive amyloid deposits in muscle fibers of inclusion-body myositis and brain of Alzheimer disease using fluorescence technique. Neurology 1993;43:1265-1267.
26. Askanas V, Alvarez RB, Mirabella M, et al: Use of antineurofilament antibody to identify paired-helical filaments in inclusion-body myositis. Ann Neurol 1996;39:389-391.
27. Engel WK, Cunningham GG: Rapid examination of muscle tissue - an improved trichrome method for fresh-frozen biopsy sections. Neurology 1963;13:919-923.
28. Askanas V, Serdaroglu P, Engel WK, et al: Immunocytochemical localization of ubiquitin in inclusion-body myositis allows its light-microscopic distinction from polymyositis. Neurology 1992;42:460-461.
29. Prayson RA, Cohen ML: Ubiquitin immunostaining and inclusion body myositis: Study of 30 patients with inclusion body myositis. Hum Pathol 1997;28:887-892.
30. Alvarez RB, Simmons Z, Engel WK: New autosomal-dominant inclusion-body myopathy (AD-IBM) with many congophilic muscle nuclei that contain paired-helical filaments (PHFs) composed of phosphorylated tau. Neurology 1998;50:A204.
31. Mirabella M, Alvarez RB, Bilak M, et al: Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies. J Neuropathol Exp Neurol 1996;55:774-786.
32. Mirabella M, Alvarez RB, Engel WK, et al: Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion body myositis and myopathies. Ann Neurol 1996;40:864-872.
33. Askanas V, Alvarez RB, Sarkozi E, et al: Partial expression of oculopharyngeal muscular dystrophy (OPMD) muscle fibers of the intracellular phenotype of sporadic inclusion-body myositis (s-IBM). Neurology 1997;48:A331.
34. Tomé FMS, Fardeau M: Hereditary inclusion body myopathies. Curr Opin Neurol 1998;11:453-459.
35. Hardy J: The Alzheimer family of diseases: Many etiologies, one pathogenesis? Proc Natl Acad Sci U S A 1997;94:2095-2097.
36. Ellis RJ, Pinheiro TJT: Danger - misfolding proteins. Nature 2002;416:483-484.
37. Bucciantini M, Giannoni E, Chiti F, et al: Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002;416:507-511.
38. Sherman MY, Goldberg AL: Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases. Neuron 2001;29:15-32.
39. Rajan RS, Illing ME, Bence NF, et al: Specificity in intracellular protein aggregation and inclusion body formation. Proc Natl Acad Sci U S A 2001;98:13060-13065.
40. Vattemi G, Engel WK, Askanas V: Evidence of endoplasmic reticulum stress and unfolded protein response in inclusion-body myositis (IBM) muscle. Neurology 2002;58:A491.
41. Ma Y, Hendershot LM: The unfolding tale of the unfolded protein response. Cell 2001;107:827-830.
42. Askanas V, McFerrin J, Baque S, et al. Transfer of β-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc Natl Acad Sci U S A 1996;93:1314-1319.
43. Askanas V, McFerrin J, Alvarez RB, et al: βAPP gene transfer into cultured human muscle induces inclusion-body myositis aspects. Neuroreport 1997;8:2155-2158.
44. McFerrin J, Engel WK, Askanas V: Impaired innervation of cultured human muscle overexpressing βAPP experimentally and genetically: Relevance to inclusion-body myopathies. Neuroreport 1998;9:3201-3205.
45. Mahley RW, Rall SC Jr: Type III hyperlipoproteinemia (dysbetalipoproteinemia): The role of apolipoprotein E in normal and abnormal lipoprotein metabolism, in Scriver CR, Beaudet AL, Sly WS (eds): Metabolic and Molecular Bases of Inheritied Diseases, 8th ed. New York, McGraw-Hill, 2001, 2863-2913.
46. Jaworska-Wilczynska M, Wilczynski GM, Engel WK, et al: Three lipoprotein receptors and cholesterol in inclusion-body myositis muscle. Neurology 2002;58:438-445.
47. Kefi M, Vattemi G, Engel WK, et al: Abnormal accumulation of caveolin-1 and its co-localization with cholesterol, amyloid-β and phosphorylated tau in inclusion-body myositis (IBM) muscle. Neurology 2002;58:A391.
48. Fielding CJ, Fielding PE: Cholesterol and caveolae: Structural and functional relationships. Biochem Biophys Acta 2000;1529:210-222.